ClinicalTrials.gg

Program

Fenretinide

Also written as “LAU-7b”, “LAU-7b for 3 cycles” and “ISLA101”.

Its studies are mostly in Lymphoma, T-Cell · Small Cell Lung Carcinoma · Post-Acute COVID-19 Syndrome · Inflammation · Dengue, led by 5 companies.

Furthest: phase 3, since May 28, 20209 company-led studies, 2 open or runningNext primary completion: May 1, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Laurent Pharmaceuticals30 open or runningphase 3since May 28, 2020Feb 21, 2017none ahead
Island Pharmaceuticals20 open or runningphase 2since Jul 15, 2024Oct 25, 2023none ahead
SciTech Development22 open or runningphase 1since Jan 13, 2020Jan 13, 2020May 1, 2027phase 1 · NCT06922539
CerRx10 open or runningphase 2since Jul 7, 2015Jul 7, 2015none ahead
Sirion Therapeutics10 open or runningphase 2since Jan 30, 2007Jan 30, 2007none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 30, 2007First study: phase 2 study in Geographic AtrophyNew to Sirion TherapeuticsSirion Therapeutics · NCT00429936 · 245 enrolled
  2. Jul 7, 2015CerRx's first study: phase 2 study in Lymphoma, T-Cell, PeripheralNew to CerRxCerRx · NCT02495415 · 140 enrolled · United States
  3. Feb 21, 2017Laurent Pharmaceuticals's first study: phase 2 study in Cystic FibrosisNew to Laurent PharmaceuticalsLaurent Pharmaceuticals · NCT03265288 · 166 enrolled · United States, Australia, Canada
  4. Jan 13, 2020SciTech Development's first study: phase 1 study in Lymphoma, T-CellNew to SciTech DevelopmentSciTech Development · NCT04234048 · 46 planned · United States
  5. May 28, 2020Phase 3 study in InflammationLaurent Pharmaceuticals · NCT04417257 · 351 enrolled · United States, Canada
  6. Aug 11, 2023Phase 3 study in Post-Acute COVID-19 SyndromeLaurent Pharmaceuticals · NCT05999435 · 272 enrolled · Canada
  7. Oct 25, 2023Island Pharmaceuticals's first study: phase 1 study in Safety and TolerabilityNew to Island PharmaceuticalsIsland Pharmaceuticals · NCT06181760 · 25 enrolled · Australia
  8. Jul 15, 2024Phase 2 study in DengueIsland Pharmaceuticals · NCT06528457 · 15 enrolled · United States
  9. Mar 22, 2025Phase 1 study in Small Cell Lung CarcinomaSciTech Development · NCT06922539 · 44 planned · United States

Ahead

  1. May 1, 2027Primary completion: phase 1 study in Small Cell Lung CarcinomaSciTech Development · NCT06922539
  2. Jun 1, 2028Primary completion: phase 1 study in Lymphoma, T-CellSciTech Development · NCT04234048

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 9 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06922539Small Cell Lung Carcinoma · United States1RecruitingSciTech DevelopmentMay 1, 202744
NCT06528457Dengue · United States2CompletedIsland PharmaceuticalsMay 21, 202515
NCT06181760Safety and Tolerability · Australia1CompletedIsland PharmaceuticalsFeb 13, 202425
NCT05999435Post-Acute COVID-19 Syndrome · Canada3CompletedLaurent PharmaceuticalsAug 5, 2024272
NCT04417257Inflammation · United States, Canada3TerminatedLaurent PharmaceuticalsFeb 15, 2024351
NCT04234048Lymphoma, T-Cell · United States1RecruitingSciTech DevelopmentJun 1, 202846
NCT03265288Cystic Fibrosis · United States, Australia, Canada2CompletedLaurent PharmaceuticalsSep 15, 2021166
NCT02495415Lymphoma, T-Cell, Peripheral · United States2UNKNOWNCerRxJul 2021140
NCT00429936Geographic Atrophy2CompletedSirion TherapeuticsMay 2010245

How it is read

Names in the registry

  • “Fenretinide”, 6 entries
  • “LAU-7b”, 2 entries
  • “LAU-7b for 3 cycles”, 1 entry
  • “ISLA101”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.